GlassScriptPhysician profile
Michael L Wood
NPI 1508995150
$14,301.58
in general payments reported to CMS, 2019-2025
38 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $818 · 2021: $1,112 · 2022: $8,203 · 2023: $1,152 · 2024: $796 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $6,675.00 | 2022 | |
| Medtronic, INC. | $1,132.24 | 2021-2025 | Micra, Linq II, In.Pact Admiral |
| Novartis Pharmaceuticals Corporation | $807.00 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.90 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $660.54 | 2019-2024 | Xarelto |
| Abbott Laboratories | $611.48 | 2019-2025 | Diamondback Peripheral, Jeti Peripheral Catheter, Jeti |
| Pfizer INC. | $450.26 | 2019-2024 | |
| Medtronic Vascular, INC. | $408.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $339.10 | 2019-2023 | Farxiga |
| Amgen INC. | $288.63 | 2019-2025 | Repatha, Repatha |
| W. L. Gore & Associates, INC. | $254.87 | 2019-2024 | C3 Delivery System, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Angiodynamics, INC. | $249.79 | 2020-2024 | Auryon Laser System 100-120 Vac, Alphavac |
| Shockwave Medical, INC | $239.56 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $205.81 | 2019-2025 | Rotablator Rotational Atherectomy System Console Kit, Watchman Flx, Ranger |
| E.R. Squibb & Sons, L.L.C. | $189.42 | 2019-2023 | Eliquis, Camzyos |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.49 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abiomed | $124.58 | 2020-2025 | Impella |
| Edwards Lifesciences Corporation | $106.96 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cardiovascular Systems INC. | $88.20 | 2019-2023 | Diamondback Peripheral |
| Cvrx, INC. | $79.40 | 2022 | |
| Surmodics, INC. | $73.00 | 2023-2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Pounce Venous Thrombectomy System |
| Lilly USA, LLC | $53.03 | 2022-2023 | Trulicity, Mounjaro |
| Lemaitre Vascular, INC. | $46.54 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $46.48 | 2019 | |
| Penumbra, INC. | $46.03 | 2024 | Indigo System |
| Terumo Medical Corporation | $43.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.42 | 2022-2023 | Xifaxan |
| Irhythm Technologies, INC. | $26.24 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $26.21 | 2025 | Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $22.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.71 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.76 | 2019 | |
| Esperion Therapeutics, INC. | $18.37 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $16.41 | 2022 | |
| Getinge USA Sales, LLC | $14.12 | 2020 | |
| Inari Medical, INC. | $13.50 | 2021 | |
| Bard Peripheral Vascular, INC. | $13.07 | 2021 | |
| Amarin Pharma, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.